In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.
A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.
On June 2, 2022, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) hosted a Roundtable on Access to Multi-disease Molecular Diagnostics, which brought together country program representatives, donors, members of civil society, and other global health actors to: Identify…
This year we celebrate the unending dedication and accomplishments of TAG’s staff. They persevered through the challenges of an ongoing pandemic in 2021 to find new ways to carry out our work.
On May 18, 2022, Treatment Action Group (TAG), the Black AIDS Institute (BAI), and the Southern AIDS Coalition (SAC) participated in this fun and informative Instagram Live discussion commemorating HIV Vaccine Awareness. Day.
As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing 12 countries, vast civil society networks, and people living with and affected by malaira, HIV, tuberculosis, and hepatitis C across the world – in reflection of World Malaria Day on April 25, 2022 – we are shocked and united in anger at the health disparities and slow progress in meeting malaria eradication goals set out in the WHO Global Technical Strategy for Malaria 2016-2030.
Treatment Action Group (TAG) and the Coalition of Women Living with HIV and AIDS (COWLHA) hosted this webinar on how community-led monitoring (CLM) can be used to assess, document, and improve the availability, accessibility, acceptability, and quality of local TB screening and diagnostic services.
This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about molnupiravir: what it is, how to take it, who should use it (and who should not,) and how it interacts with other drugs.
At the first of these two public hearings TAG submitted the following statement with six reasons why the new international instrument must explicitly acknowledge the right to science as a central guiding framework.
Paxlovid can reduce the risk of hospitalization or death by 89% when taken shortly after testing positive for COVID-19. This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about Paxlovid: what it is,…